Advertisement

Current Breast Cancer Reports

, Volume 8, Issue 3, pp 151–157 | Cite as

Screening for Cognitive Impairment Associated with Chemotherapy for Breast Cancer

  • Diane F. MoreanEmail author
  • Leora R. Cherney
Clinical Trials (S Hurvitz, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Clinical Trials

Abstract

At least 20 % of women treated with chemotherapy for breast cancer experience some form of cognitive decline. Recent recommendations call for clinicians to screen cognitive abilities. Screening of factors that can contribute to cognitive impairment is also currently recommended. We describe a battery of free, online, self-report surveys that would take approximately 30 min to complete in the context of an overall functional assessment of wellness. Key physical characteristics to be screened include fatigue and insomnia. Significant psychological characteristics include distress, depression, and anxiety. Fundamental social characteristics include basic needs, workplace issues, and interpersonal well-being. Systematic screening that could be completed in the clinic waiting room or during chemotherapy infusion is an important first step towards more holistic patient care that addresses cognitive side effects, just as physical side effects of treatment are routinely addressed.

Keywords

Breast neoplasms Adjuvant chemotherapy Adverse effects Brain Cognition Cognition disorders Memory Executive function Fatigue Psychological stress Depression Anxiety Surveys and questionnaires Survivors Quality of life 

Notes

Acknowledgments

The study was supported by an Advanced Rehabilitation Research Training Award: Interventions for Neurologic Communication Disorders (award no. 90AR5015-01-00) from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) and the Evergreen Invitational Women’s Health Grants Initiative. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Compliance with Ethical Standards

Conflict of Interest

Diane F. Morean and Leora R. Cherney declare that they have nothing to declare.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    World Health Organization. Cancer: fact sheet 297. 2015. Retrieved from http://www.who.int/mediacentre/factsheets/fs297/en/Google Scholar
  2. 2.
    American Cancer Society. Global cancer facts and figures, 2nd edition. 2008. Retrieved from http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf
  3. 3.
    Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65:5–29. doi: 10.3322/caac.21254.CrossRefPubMedGoogle Scholar
  4. 4.
    Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3:S84–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology. 1995;4:61–6. doi: 10.1002/pon.2960040108.CrossRefGoogle Scholar
  6. 6.
    Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.CrossRefPubMedGoogle Scholar
  7. 7.
    Collins B, Mackenzie J, Kyeremanteng C. Study of the cognitive effects of chemotherapy: considerations in selection of a control group. J Clin Exp Neuropsychol. 2013;35:435–44. doi: 10.1080/13803395.2013.781995.CrossRefPubMedGoogle Scholar
  8. 8.
    Myers JS. Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum. 2012;39:E31–40. doi: 10.1188/12.CrossRefPubMedGoogle Scholar
  9. 9.
    Ando-Tanabe N, Iwamitsu Y, Kuranami M, Okazaki S, Yasuda H, Nakatani Y, et al. Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls. Breast Cancer. 2012;21:453–62. doi: 10.1007/s12282-012-0405-7.CrossRefPubMedGoogle Scholar
  10. 10.
    Andreano JM, Waisman J, Donley L, Cahill L. Effects of breast cancer treatment on the hormonal and cognitive consequences of acute stress. Psycho-Oncology. 2012;21:1091–8. doi: 10.1002/pon.2006.CrossRefPubMedGoogle Scholar
  11. 11.
    Berman MG, Askren MK, Jung M, Therrien B, Peltier S, Noll DC, et al. Pretreatment worry and neurocognitive responses in women with breast cancer. Health Psychol. 2014;33:222–31. doi: 10.1037/a0033425.CrossRefPubMedGoogle Scholar
  12. 12.
    Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psycho-Oncology. 2012;21:43–53. doi: 10.1002/pon.1860.CrossRefPubMedGoogle Scholar
  13. 13.
    Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology. 2009;18:811–21. doi: 10.1002/pon.1453.CrossRefPubMedGoogle Scholar
  14. 14.
    Hurria A, Somlo G, Ahles T. Renaming “chemobrain”. Cancer Investig. 2007;25:373–7. doi: 10.1080/07357900701506672.CrossRefGoogle Scholar
  15. 15.
    Shilling V, Jenkins V, Fallowfield J, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405–12. doi: 10.1016/j.jsbmb.2003.07.001.CrossRefPubMedGoogle Scholar
  16. 16.
    Butow PN, Phillips F, Schweder J, White K, Underhill C, Goldstein D. Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review. Support Care Cancer. 2012;20:1–22. doi: 10.1007/s00520-011-1270-1.CrossRefPubMedGoogle Scholar
  17. 17.
    Hendren S, Chin N, Fisher S, Winters P, Griggs J, Mohile S, et al. Patients’ barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc. 2011;103:701–10. doi: 10.1016/S0027-9684(15)30409-0.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.•
    Wagner LI, Spiegel D, Pearman T. Using the science of psychosocial care to implement the new American College of Surgeons commission on cancer distress screening standard. J Natl Compr Cancer Netw. 2013;1:214–21. This focused review provides practical information on implementing screening standards into routine breast cancer treatment. Google Scholar
  19. 19.
    Boykoff N, Moieni M, Subramamian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3:223–32. doi: 10.1007/s11764-009-0098-x.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008;26:768–77. doi: 10.1200/JCO.2007.14.3248.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, Dantzer R, et al. Review article: mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci. 2015;9:131. doi: 10.3389/fnins.2015.00131.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8:88–91. doi: 10.3816/CBC.2008.n.007.CrossRefPubMedGoogle Scholar
  23. 23.
    de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83. doi: 10.1002/hbm.21422.CrossRefPubMedGoogle Scholar
  24. 24.
    Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81. doi: 10.1200/JCO.2011.36.8571.CrossRefPubMedGoogle Scholar
  25. 25.
    Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11. doi: 10.1007/s10549-006-9380-z.CrossRefPubMedGoogle Scholar
  26. 26.••
    Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34:611–35. doi: 10.1200/JCO.2015.64.3809. This ASCO special article provides recommendations to assist primary care and other clinicians in the care of breast cancer survivors, including assessment and management of cognitive impairment and contributing factors of cognitive impairment. CrossRefPubMedGoogle Scholar
  27. 27.••
    American College of Surgeons Commission on Cancer (2016). Cancer program standards: ensuring patient-centered care manual, 2016 edition. Retrieved from https://www.facs.org/~/media/files/quality%20programs/cancer/coc/2016%20coc%20standards%20manual_interactive%20pdf.ashx. This manual describes CoC accreditation requirements including psychosocial distress screening and navigation.
  28. 28.
    Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.PubMedGoogle Scholar
  29. 29.
    Wagner L, Sweet J, Butt Z, Lai J, Cella D. Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy–Cognitive Function instrument. J Support Oncol. 2009;7:W32–9.Google Scholar
  30. 30.
    Dumas JA, Makarewicz J, Schaubhut GJ, Devins R, Albert K, Dittus K, et al. Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging Behav. 2013;7:524–32. doi: 10.1007/s11682-013-9244-1.CrossRefPubMedGoogle Scholar
  31. 31.
    López Zunini RA, Scherling C, Wallis N, Collins B, MacKenzie J, Bielaiew C, et al. Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav. 2013;7:460–77. doi: 10.1007/s11682-012-9213-0.CrossRefPubMedGoogle Scholar
  32. 32.
    Herrera C, Chambon C, Michel BF, Paban V, Alescio-Lautier B. Positive effects of computer-based cognitive training in adults with mild cognitive impairment. Neuropsychologia. 2012;50:1871–81. doi: 10.1016/j.neuropsychologia.2012.04.012.CrossRefPubMedGoogle Scholar
  33. 33.
    Conroy SK, McDonald BC, Ahles TA, West JD, Saykin AJ. Chemotherapy-induced amenorrhea: a prospective study of brain activation changes and neurocognitive correlates. Brain Imaging Behav. 2013;7:491–500. doi: 10.1007/s11682-013-9240-5.CrossRefPubMedGoogle Scholar
  34. 34.
    Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006;15:921–30. doi: 10.1002/pon.1035.CrossRefPubMedGoogle Scholar
  35. 35.
    Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21:364–71. doi: 10.1016/j.neuroimage.2003.08.037.CrossRefPubMedGoogle Scholar
  36. 36.
    Evangelista AL, Santos EM. Cluster of symptoms in women with breast cancer treated with curative intent. Support Care Cancer. 2012;20:1499–506. doi: 10.1007/s00520-011-1238-1.CrossRefPubMedGoogle Scholar
  37. 37.
    Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;1:61–66.0. doi: 10.1002/pon.709.CrossRefGoogle Scholar
  38. 38.
    Lyon DE, Cohen R, Chen H, Kelly DL, Starkweather A, Ahn H et al. The relationship of cognitive performance to concurrent symptoms, cancer- and cancer-treatment-related variables in women with early-stage breast cancer: a 2-year longitudinal study. J Cancer Res Clin Oncol. 2016, 1-14. doi:  10.1007/s00432-016-2163-y
  39. 39.
    Pinto AC, de Azambuja E. Improving quality of life after breast cancer: dealing with symptoms. Maturitas. 2011;70:343–8. doi: 10.1016/j.maturitas.2011.09.008.CrossRefPubMedGoogle Scholar
  40. 40.
    Pullens MJ, De Vries J, Van Warmerdam LJ, Van De Wal MA, Roukema JA. Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology. 2013;22:1783–9. doi: 10.1002/pon.3214.CrossRefPubMedGoogle Scholar
  41. 41.
    Reid-Arndt SA, Yee A, Perry MC, Hsieh C. Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. Psychosoc Oncol. 2009;27:415–34. doi: 10.1080/07347330903183117.CrossRefGoogle Scholar
  42. 42.
    Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symp Manag. 1999;18:233–42.CrossRefGoogle Scholar
  43. 43.
    Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, et al. NCCN Practice guidelines for cancer-related fatigue. Oncology. 2000;14:151–61.PubMedGoogle Scholar
  44. 44.
    de Jong N, Courtens AM, Abu-Saad HH, Schouten HD. Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature. Cancer Nurs. 2002;25:283–97.CrossRefPubMedGoogle Scholar
  45. 45.
    Sitzia J, Huggins L. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Pract. 1998;6:13–21. doi: 10.1046/j.1523-5394.1998.1998006013.x.CrossRefPubMedGoogle Scholar
  46. 46.
    Jacobsen PB, Garland LL, Booth-Jones M, Donovan KA, Thors CL, Winters E, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manag. 2004;28:7–18. doi: 10.1016/j.jpainsymman.2003.11.002.CrossRefGoogle Scholar
  47. 47.
    National Heart Lung and Blood Institute. What causes anemia? 2012. Retrieved from http://www.nhlbi.nih.gov/health/health-topics/topics/anemia/causes
  48. 48.
    Smith E, Lai JS, Cella D. Building a measure of fatigue: the Functional Assessment of Chronic Illness Therapy Fatigue Scale. PMR. 2010;2:359–63. doi: 10.1016/j.pmrj.2010.04.017.CrossRefGoogle Scholar
  49. 49.
    Bastien CH, VallieÁres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307. doi: 10.1016/S1389-9457(00)00065-4.CrossRefPubMedGoogle Scholar
  50. 50.
    Sateia MJ, Lang BJ. Sleep and cancer: recent developments. Curr Oncol Rep. 2008;10:309–18.CrossRefPubMedGoogle Scholar
  51. 51.
    Airaksinen E, Larsson M, Lundberg I, Forsell Y. Cognitive functions in depressive disorders: evidence from a population-based study. Psychol Med. 2004;34(1):83–91.CrossRefPubMedGoogle Scholar
  52. 52.
    Airaksinen E, Larsson M, Forsell Y. Neuropsychological functions in anxiety disorders in population-based samples: evidence of episodic memory dysfunction. J Psychiatr Res. 2005;39:207–14. doi: 10.1016/j.jpsychires.2004.06.001.CrossRefPubMedGoogle Scholar
  53. 53.
    Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30:112–26. doi: 10.1016/j.genhosppsych.2007.10.008.CrossRefPubMedGoogle Scholar
  54. 54.
    Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74. doi: 10.1016/S1470-2045(11)70002-X.CrossRefPubMedGoogle Scholar
  55. 55.
    Lovibond SH, Lovibond PF. Manual for the depression anxiety stress scales. 2nd ed. Sydney: Psychology Foundation; 1995.Google Scholar
  56. 56.
    Bauer A. Cancer.net, Spotlight on: oncology social workers–Part I, a Q&A. 2014. Retrieved from http://www.cancer.net/blog/2014-04/spotlight-oncology-social-workers-%E2%80%93-part-i-qa
  57. 57.
    Web Finance Inc. Work environment. 2014. Retrieved from http://www.businessdictionary.com/definition/work-environment.html
  58. 58.
    Morean DF, O’Dwyer L, Cherney LR. Therapies for cognitive deficits associated with chemotherapy for breast cancer: a systematic review. Arch Phys Med Rehabil. 2015;96:1880–97.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Rehabilitation Institute of ChicagoChicagoUSA
  2. 2.Feinberg School of MedicineNorthwestern UniversityChicagoUSA

Personalised recommendations